Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI:10.1080/14796694.2025.2542030

José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar

{"title":"Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study.","authors":"José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar","doi":"10.1080/14796694.2025.2542030","DOIUrl":null,"url":null,"abstract":"Aim: Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.Method: We conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.Results: A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.Conclusions: During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2767-2774"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407652/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2542030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.

Method: We conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.

Results: A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.

Conclusions: During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.

Abstract Image

查看原文本刊更多论文

西班牙RCC一线及后续治疗模式。一个真实世界的描述性横断面研究。

目的：晚期肾细胞癌（RCC）治疗方案有限，预后较差。最初，酪氨酸激酶抑制剂（TKIs）增加了无进展生存期（PFS），并允许识别良好（FP），中间（IP）和不良预后（PP）亚组。虽然TKI仍然是FP患者的一种选择，但在总体人群中，免疫检查点抑制剂（IO）加TKI，或在IP/PP患者中使用IO/IO，已经提高了总生存期（OS），并已成为标准的治疗方法。然而，它们在临床实践中的采用因国家而异。方法：我们使用Oncology Dynamics™数据库进行了一项横断面观察性研究，以评估西班牙的治疗模式。结果：共登记了1587例转移性RCC （mRCC）患者，900例接受了透明细胞mRCC （mccRCC）的一线治疗。2022年，在肿瘤学家治疗的mccRCC FP患者中（N = 137）， 92.7%接受了TKIs；而IP/PP患者（N = 298）， 56.7%接受TKIs， 27.5%接受抗pd1 - antitla4, 13.8%接受抗pd1 - tki。2023年，mccRCC FP患者（N = 124）的TKIs为94.4%；IP/PP患者（N = 256）的TKIs为48.4%，antipd1 - antitla4为38.3%，antiPD1-TKI为12.1%。结论：在此期间，西班牙临床实践中IO/IO和IO/TKI的摄取低于目前建议的预期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.